LYRA News and Press, Lyra Therapeutics Inc. From 08/09/22

Lyra Therapeutics press release ( NASDAQ: LYRA ): Q2 GAAP EPS of -$0.43. Revenue of $0.4M. Cash and cash equivalents as of June 30, 2022 were $120.7 million, compared with $33.8 million at March 31, 2022. The Company expects its cash and c...

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of chronic rhinosinusitis (CRS) patients, continued...

Lyra Therapeutics ( NASDAQ: LYRA ) has appointed Dr. Richard Nieman as Chief Medical Officer, effective July 11, 2022. The industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the company's late-st...

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer PR Newswire Industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the Company's late-stage product candidates advance...

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 PR Newswire WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo...

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WATERTOWN, Mass. , June 17, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprieta...

Cantor Fitzgerald initiated Lyra Therapeutics (NASDAQ:LYRA) with an overweight rating saying the company's pipeline is not appreciated enough. The firm has a $15 price target (~147% upside based on Monday's close). Analyst Louise Chen highlighted two candidates in particular, LYR-210 and LYR-...

Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile. The company is well funded. In this risk-off environment, there may be an even better entry point for investors. For further details see: Lyra Therapeutics: Progress ...

Lyra Therapeutics press release (NASDAQ:LYRA): Q1 GAAP EPS of -$0.54 beats by $0.38. Revenue of $5.37M beats by $4.12M. Cash and cash equivalents as of March 31, 2022 were $33.8 million, compared with $45.7 million at December 31, 2021. The Company expects its ca...

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire In April 2022 , secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data...